2016 Original PMAs And Panel-Track Supplements
This article was originally published in The Gray Sheet
Executive Summary
A sortable and searchable table of FDA original PMAs and panel-track supplements approved in calendar year 2016, updated monthly. Latest update: approvals through June 30.
You may also be interested in...
First Blood-Based Lung Cancer EGFR Test Gets Green Light
FDA has approved the first liquid biopsy test to detect genetic mutations linked to drug response in patients with non-small cell lung cancer. Roche's cobas EGFR Mutation Test v2 could be a game-changer in helping to diagnose certain NSCLC patients without requiring a tumor biopsy, the agency suggests.
Teva’s ‘Skinny Label’ Dispute Edges Toward Supreme Court With Government’s Backing
US Solicitor General urges the Supreme Court to grant Teva's petition, arguing that the Federal Circuit was wrong in ruling that Teva's carved-out labeling for generic carvedilol induced infringement of GlaxoSmithKine's brand product.
UK Updates Guidance To Reflect EU Medtech Extensions
The EU’s decision to extend the Medical Device Regulation transition periods for legacy medical device directives products will be mirrored in the UK, which also continues to evolve its post-Brexit medtech regulatory system.